Ibandronate Sodium

CHEMBL3989569 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
359.2 g/mol
LogP
Phase
4

This sodium salt of ibandronate is a bisphosphonate used to treat osteoporosis in postmenopausal women and bone metastases from breast cancer. It reduces bone resorption by inhibiting osteoclasts, which helps to strengthen bones and reduce fracture risk. Monthly oral tablets or quarterly intravenous infusions are available.

น้ำหนักโมเลกุล

359.2300 g/mol

TPSA

142.00 Ų

ด้านการรักษา

กลไกการออกฤทธิ์

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCCCCN(C)CCC(O)(P(=O)([O-])O)P(=O)(O)O.O.[Na+]

InChI

InChI=1S/C9H23NO7P2.Na.H2O/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17;;/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17);;1H2/q;+1;/p-1

Molecular Formula

C9H24NNaO8P2

HBD / HBA

5 / 9

พันธะที่หมุนได้

9

อะตอมหนัก

21

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

This sodium salt of ibandronate is a bisphosphonate used to treat osteoporosis in postmenopausal women and bone metastases from breast cancer. It reduces bone resorption by inhibiting osteoclasts, which helps to strengthen bones and reduce fracture risk. Monthly oral tablets or quarterly intravenous infusions are available.

Binds to hydroxyapatite crystals in bone, inhibiting osteoclast-mediated bone resorption by disrupting the mevalonate pathway within osteoclasts. This reduces bone turnover and increases bone mineral density.

Yes, Ibandronate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989569. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 23663991. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.